They singled out Novo Nordisk for its recent discontinuation of the long-acting Levemir because one narrator ... a competitor’s basal insulin (Lantus), at a 78% lower price.” ...

Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

Zenchenko is among the parents stockpiling Levemir, trying to put off what he fears would be a difficult transition for his son back to the pump or to Lantus. "It's tough to explain to him that ...

There are several other basal insulin options available besides Levemir, she added, including Eli Lilly's Basaglar and Rezvoglar, as well as Sanofi's long-acting insulin Lantus or its Viatris-made ...

“My 15-year-old daughter has great management using Levemir. The thought of it not being available was, and is, incomprehensible to me.” Smart explained that her daughter has tried other insulins, ...

For example, someone who’s taking 20 units of Levemir at night will likely be transitioned to 20 units of Lantus. “They’re similar and work in approximately 24 hours,” he said. After switching ...

Levemir is one of three types of long-acting "basal" insulins, but it doesn't last in the body as long as other basal versions. Lantus lasts 24 to 36 hours, and Tresiba lasts up to 42 hours.

Sanofi cut the list price of Lantus by 78% to $96 for the prefilled ... including NovoLog, Novolin and Levemir, by up to 75% as of January 1. The new list price for NovoLog is $72 per vial and ...